The rapid development of drug nanocarriers has benefited from the surface hydrophilic
polymers of particles, which has improved the pharmacokinetics of the drugs. Polyethylene …

Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

In recent years, the development of nanoparticles has expanded into a broad range of
clinical applications. Nanoparticles have been developed to overcome the limitations of free …

Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative diseases, affecting millions and costing billions each year in the United …

Stimuli-responsive polymers can respond to internal stimuli, such as reactive oxygen
species (ROS), glutathione (GSH), and pH, biological stimuli, such as enzymes, and external …

The advent of genome editing has transformed the therapeutic landscape for several
debilitating diseases, and the clinical outlook for gene therapeutics has never been more …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Effective anticancer nanomedicines need to exhibit prolonged circulation in blood, to
extravasate and accumulate in tumours, and to be taken up by tumour cells. These …